Print Page      Close Window     


SEC Filings

OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document



OBE2109: Potential best-in-class, oral, GnRH receptor antagonist OBE2109 AT-A-GLANCE • GnRH ReceptorAntagonist • OBE2109 (KLH-2109) • Licensed from Kissei (WW rights, excludesAsia) • IP Protection* to 2036 (COM 2032) • > 1400 female subjects exposed to date OBE2109 INDICATIONS • Uterine Fibroids • Symptoms: Heavy menstrual bleeding and abdominal pain • Primary goal is to reduce/eliminate bleeding • Endometriosis • Symptoms: pain and infertility • Primary goal is to alleviate pain Landscape Standard of Care:    Esmya/Fibristal® Elagolix Relugolix Lupron, SPRM approved in EU/Canada(AbbVie/Neurocrine) in Phase 3 (Myovant/Takeda) in oral contraceptives, surgery for uterine fibroids, U.S. NDADevelopment for fibroids, U.S. NDAPhase 3 Development submittedsubmitted for endometriosis * Including PTA/PTE (Patent Term Adjustment / Patent Term Extension)